Company: SCLXW
Filing Date: 2025-12-16
Form Type: S-1
Source: 0001193125-25-319720
Chunk: 236

Company: Scilex Holding Co
Filing Date: 2025-12-16
Form: S-1
Chunk 236
---
 from time to time, to Tumim up to $100.0 million in aggregate gross purchase price of shares of Common Stock in our sole discretion, subject to certain conditions and limitations, during the term of 24 months. Through September 30, 2025, there were no sales of shares of Common Stock under the Tumim Purchase Agreement.

In connection with the Tumim Purchase Agreement, we incurred an obligation to issue 150,000 shares of Common Stock (“Commitment Shares Obligation”) to Tumim. The Commitment Shares Obligation was determined to be an equity-linked contract and met all the conditions for equity classification. We recognized an amount of $3.0 million in expense and in accrued expenses.

During the three months ended September 30, 2025, there were no sales of shares of Common Stock under the Tumim Purchase Agreement. On October 30, 2025, Tumim and the Company entered into a termination

<div align='center'>155</div>

agreement (the “Termination Agreement”), pursuant to which the Tumim Purchase Agreement and Tumim Registration Rights Agreement will terminate upon payment in full of the cash consideration due under the Termination Agreement, with such final payment due on December 15, 2025. Warrant Exercise Agreement On September 30, 2025, we entered to the Warrant Exercise Agreement with certain holders of the December 2024 RDO Common Warrants, pursuant to which, among other things, such holders exercised the December 2024 RDO Common Warrants to purchase 179,236 shares and deferred, for a deferral fee of $7.72 per share being exercised, their right to receive an amortization payment scheduled to be paid by us on October 1, 2025 as set forth in the amortization schedule included in the Tranche B Notes in exchange for our agreement to issue the September 2025 Warrants to purchase an aggregate of 275,000 shares of Common Stock at an exercise price of $20.00 per share. Semnur Business Combination On September 22, 2025, the Company, together with Denali, Denali Merger Sub and Legacy Semnur, consummated the Semnur Business Combination. In connection with the Semnur Business Combination, Denali changed its name from Denali Capital Acquisition Corp. to Semnur Pharmaceuticals, Inc. Pursuant to the Semnur Business Combination, the Company acquired all of the issued and